Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

34.26 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
31 32 Next >
CRISPR Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Analyst Expectations for CRISPR Therapeutics's Future
Via Benzinga
A Good Week For The Market But A Pause In The Biotech Rally
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
Cathie Wood Just Sold CRISPR Therapeutics Stock. Here's Why You Should Consider Buying It
Her investing thesis for holding it is probably the same as ever. 
Via The Motley Fool
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher. 
Via InvestorPlace
Is CRISPR Therapeutics Stock a Buy Now?
The clinical-stage biotech company has been on the rise. 
Via The Motley Fool
Is It Too Late to Buy CRISPR Stock?
Five reasons to buy the promising biotech stock now. 
Via The Motley Fool
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Exposures Product Safety
2 Stocks You'll Be Glad You Bought at These Prices
Bear markets create opportunities to buy high-growth stocks at discounted valuations. 
Via The Motley Fool
2 Soaring Growth Stocks That Could Rocket Even Higher
One of these stocks is up 57% this year, and the other one has more than tripled already. 
Via The Motley Fool
Why These 3 Nasdaq Stocks Were Glowing Green This Week
These three biopharmaceutical stocks rocketed higher this week. 
Via The Motley Fool
Devon Energy, CRISPR Therapeutics, And Bullish On Berkshire Succession: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joseph Terranova of Virtus Investment Partners said CRISPR Therapeutics AG (NASDAQ: CRSP) reported strong 
Via Benzinga
Why CRISPR Therapeutics Stock Is on Fire Today
Thanks to the gene-editing pioneer having a pipeline chock-full of deep value and a possible regulatory approval on tap, investors are bidding up shares today. 
Via The Motley Fool
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
This Incredible Growth Stock Has All the Hallmarks of a Prototypical Warren Buffett Stock
Vertex Pharmaceuticals faces limited competition in its core area of expertise, has a top-shelf CEO, and is building out a profoundly valuable pipeline of next-generation assets. 
Via The Motley Fool
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May
This market-beating biotech stock still has more room to run. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy in May
You'll want to hold onto these innovative companies for the long term. 
Via The Motley Fool
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
Cathie Wood is loading up on these biotech stocks. 
Via The Motley Fool
Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector
A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro... 
Via Talk Markets
Why CRISPR Therapeutics Just Became an Even Better Buy
Is this a no-brainer investment to add to your portfolio? 
Via The Motley Fool
3 Biotech Stocks to Watch After Johnson & Johnson’s Earnings Beat
Discover the latest picks in the biotech industry with our article on 3 biotech stocks to watch after Johnson & Johnson’s earnings beat. 
Via InvestorPlace
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
Via Benzinga
The Best Stocks to Invest $20,000 in Right Now
You'll want to hold on to these top stocks for the long term. 
Via The Motley Fool
Buy the Dip: 2 Top Stocks to Snatch Up Now
You don't need to be too gutsy to buy these two stocks while they're down. 
Via The Motley Fool
3 Stocks With Huge Catalysts on the Way
Big news could mean big boosts for these stocks. 
Via The Motley Fool
2 Growth Stocks That Could Keep Growing for Decades
These businesses will likely only get larger in the future. 
Via The Motley Fool
Better Big Biotech Buy: Biogen vs. Vertex
One is slightly cheaper than the other. 
Via The Motley Fool
The Top 3 Biotech Stocks to Watch in 2023
Investors would be wise to keep an eye on the biotech boom, and these top biotech stocks to watch as we get deeper into 2023. 
Via InvestorPlace
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.